Exosome is a subgroup of extracellular vesicles, which has been serving as an efficient
therapeutic tool for various diseases. Engineered exosomes are the sort of exosomes …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

Triple-negative breast cancer (TNBC) is the most metastatic and recurrent subtype of all
breast cancers. Owing to the lack of therapeutic targets, chemotherapy and surgical …

CAR T cell-based therapies have revolutionized the treatment of hematological
malignancies such as leukemia and lymphoma within the last years. In contrast to the …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising
therapeutics for many diseases, including cancer, in clinical trials. One PARP inhibitor …

Abstract c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte
growth factor (HGF), activates downstream pathways with diverse cellular functions that are …

Breast cancer has been shown to live in the tumor microenvironment, which consists of not
only breast cancer cells themselves but also a significant amount of pathophysiologically …

Breast cancer, one of the leading causes of death in women in the United States, challenges
therapeutic success in patients due to tumor heterogeneity, treatment resistance, metastasis …

The MET gene, known as MET proto-oncogene receptor tyrosine kinase, was first identified
to induce tumor cell migration, invasion, and proliferation/survival through canonical RAS …

Simple Summary Immunotherapy has made tremendous clinical progress in breast cancer.
However, in some patients, the response rate to immunotherapy is low because the tumor …